BRAIN Act
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill establishes new programs to accelerate brain tumor research and improve care for brain tumor patients. It creates the Glioblastoma Therapeutics Network with $50 million annually to evaluate new treatments, funds CAR-T immunotherapy research with $10 million annually, and launches pilot programs for brain tumor survivor care.
Who Benefits and How
Medical research institutions and cancer centers benefit from $60 million in annual authorized appropriations for grants. Brain tumor patients and survivors benefit from new treatment development, biospecimen database access, clinical trial awareness campaigns, and survivorship care programs. Pharmaceutical and biotech companies developing brain tumor therapies gain access to collaborative research networks and expedited clinical trial pathways.
Who Bears the Burden and How
Researchers and institutions holding NIH-funded brain tumor biospecimen collections must report their holdings to the NIH Director within 180 days of enactment. Healthcare providers face minor administrative tasks related to the clinical trials awareness campaign. The federal government bears the cost of the authorized appropriations (up to $60 million annually).
Key Provisions
- Establishes the Glioblastoma Therapeutics Network with $50M/year for 5 years to evaluate brain tumor treatments from pre-clinical through early-phase clinical trials
- Authorizes $10M/year for 5 years for CAR-T cellular immunotherapy research for adult and pediatric brain tumors
- Requires reporting of NIH-funded brain tumor biospecimen collections to create a public searchable database
- Creates a national public awareness campaign on cancer clinical trials and biomarker testing
- Establishes pilot programs for monitoring and caring for brain tumor survivors throughout their lifespan
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
Advances brain tumor research by establishing the Glioblastoma Therapeutics Network, funding cellular immunotherapy development, creating biospecimen transparency requirements, launching a clinical trials awareness campaign, and supporting pilot programs for brain tumor survivor care.
Key Policy Areas
Healthcare, Medical Research, Public Health
Primary Purpose
Advances brain tumor research by establishing the Glioblastoma Therapeutics Network, funding cellular immunotherapy development, creating biospecimen transparency requirements, launching a clinical trials awareness campaign, and supporting pilot programs for brain tumor survivor care.
Policy Domains
Brain Tumor Research and Care Act
Identified Gains
Contextual inference, no direct clause citation- Brain tumor patients and survivors
- Medical research institutions
- Cancer centers
- Pharmaceutical and biotech companies
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Federal government (appropriations)
- Biospecimen collection holders (reporting requirements)
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
In CommitteeMr. Blumenthal (for himself, Mr. Rounds, Mr. Reed, and Mr. …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Brain tumor survivors, Brain tumor survivors and their families, Cancer centers and community medical facilities
Brain tumor researchers seeking tissue samples, Clinical trial operators and cancer research organizations, Medical researchers studying brain tumors
Academic medical centers conducting glioblastoma research, Academic medical centers with immunotherapy programs, Medical schools and academic medical centers
Entities maintaining NIH-funded brain tumor biospecimens, Research institutions with NIH-funded biospecimen collections
Cancer clinical trial sponsors, Pharmaceutical companies developing brain tumor therapies
Biotech companies developing CAR-T immunotherapy, CAR-T therapy developers and researchers
Eligible entities providing survivorship care
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_secretary"
- → Secretary of Health and Human Services
- "director_of_nih"
- → Director of the National Institutes of Health
- "director_of_the_institute"
- → Director of the National Cancer Institute
Key Definitions
Terms defined in this bill
A biospecimen that was collected or acquired in whole or in part through funding from the National Institutes of Health
A medical school, children's hospital, cancer center, community-based medical facility, or any other entity with significant experience and expertise in brain tumor survivor care
A brain tumor tissue, cerebral spinal fluid, or other specimen type listed by the Specimen Resource Locator of the National Cancer Institute
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology